Baili Tianheng

Baili Tianheng is a leading innovative biopharmaceutical company headquartered in China, specializing in the development of next-generation oncology therapies, including multi-specific antibodies and antibody-drug conjugates (ADCs). The company operates internationally through its US-based R&D subsidiary, SystImmune, and is recognized for its sophisticated proprietary platforms that enable the design of tetraspecific antibodies and dual-targeting ADCs. Baili Tianheng achieved significant global recognition in 2023 through a multi-billion dollar strategic collaboration with Bristol Myers Squibb for its lead candidate, BL-B01D1, the first bispecific ADC to reach clinical trials globally. While the company maintains a legacy business in pharmaceutical manufacturing and sales, its primary focus has shifted toward high-impact biologics for the treatment of various solid tumors and hematologic malignancies. Its integrated approach spans the entire drug development lifecycle, from early-stage discovery to large-scale commercial manufacturing.